Zifi Drop contains Cefixime 25 mg/ml, a third-generation cephalosporin antibiotic indicated for the treatment of a variety of bacterial infections. Cefixime exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Zifi Drop is primarily used in pediatric patients for the management of infections caused by susceptible strains of gram-positive and gram-negative bacteria, including otitis media, pharyngitis, tonsillitis, urinary tract infections, and uncomplicated gonorrhea. The formulation allows for convenient oral administration with accurate dosing, enhancing compliance in pediatric populations. Cefixime demonstrates good oral bioavailability and a broad spectrum of activity, making it effective against common pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, and Proteus mirabilis. It is important to complete the full prescribed course to prevent the development of resistance and ensure eradication of the infection. Zifi Drop should be used cautiously in patients with a history of hypersensitivity to cephalosporins or penicillins. Adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain. Dose adjustments may be necessary in patients with renal impairment. As with all antibiotics, use of Zifi Drop should be guided by susceptibility testing and clinical judgment to optimize therapeutic outcomes.